Dr. William G Wierda, MD, PhD
Claim this profileM D Anderson Cancer Center
Area of expertise
Chronic Lymphocytic Leukemia
William G Wierda, MD, PhD has run 3 trials for Chronic Lymphocytic Leukemia. Some of their research focus areas include:
Chronic B-Cell Leukemia
William G Wierda, MD, PhD has run 1 trial for Chronic B-Cell Leukemia. Some of their research focus areas include:
Affiliated Hospitals
M D Anderson Cancer Center
The University Of Texas M.D. Anderson Cancer Center
Clinical Trials William G Wierda, MD, PhD is currently running
Acalabrutinib + Venetoclax ± Obinutuzumab
for Chronic Lymphocytic Leukemia
This phase II trial studies how well acalabrutinib and venetoclax with or without early obinutuzumab work for the treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma that is high risk, has come back (recurrent), or does not respond to treatment (refractory). Acalabrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Venetoclax may stop the growth cancer cells by blocking BCL-2 protein needed for cell growth. Immunotherapy with monoclonal antibodies, such as obinutuzumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving acalabrutinib and venetoclax together with early obinutuzumab may improve clinical outcomes and control the disease.
Recruiting
1 award
Phase 2
13 criteria
JCAR017
for Chronic Leukemia or Lymphoma
This trial tests JCAR017, a therapy using modified immune cells, in adults with hard-to-treat CLL or SLL. It aims to see if these enhanced immune cells can better fight the cancer.
Recruiting
1 award
Phase 1 & 2
More about William G Wierda, MD, PhD
Clinical Trial Related
5 years of experience running clinical trials · Led 3 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments William G Wierda, MD, PhD has experience with
- Venetoclax
- Acalabrutinib
- Obinutuzumab
- Ibrutinib
- JCAR017 (lisocabtagene Maraleucel)
- XmAb13676
Breakdown of trials William G Wierda, MD, PhD has run
Chronic Lymphocytic Leukemia
Chronic B-Cell Leukemia
Leukemia
Diffuse Large B-Cell Lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does William G Wierda, MD, PhD specialize in?
William G Wierda, MD, PhD focuses on Chronic Lymphocytic Leukemia and Chronic B-Cell Leukemia. In particular, much of their work with Chronic Lymphocytic Leukemia has involved del(17p) positive patients, or patients who are IGHV negative.
Is William G Wierda, MD, PhD currently recruiting for clinical trials?
Yes, William G Wierda, MD, PhD is currently recruiting for 2 clinical trials in Houston Texas. If you're interested in participating, you should apply.
Are there any treatments that William G Wierda, MD, PhD has studied deeply?
Yes, William G Wierda, MD, PhD has studied treatments such as Venetoclax, Acalabrutinib, Obinutuzumab.
What is the best way to schedule an appointment with William G Wierda, MD, PhD?
Apply for one of the trials that William G Wierda, MD, PhD is conducting.
What is the office address of William G Wierda, MD, PhD?
The office of William G Wierda, MD, PhD is located at: M D Anderson Cancer Center, Houston, Texas 77030 United States. This is the address for their practice at the M D Anderson Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.